Free Trial
OTCMKTS:GBCS

Selectis Health 6/29/2023 Earnings Report

Selectis Health logo
$2.55 +0.05 (+2.00%)
As of 07/11/2025

Selectis Health EPS Results

Actual EPS
-$0.72
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Selectis Health Revenue Results

Actual Revenue
$10.80 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Selectis Health Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Selectis Health's next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules.

Conference Call Resources

Selectis Health Earnings Headlines

Selectis Health Delays Q1 2025 10-Q Filing
Selectis Health Delays Yearly Report Filing
Revolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial Underway
Tiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!
Selectis Health Makes Key Leadership Announcement
See More Selectis Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Selectis Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Selectis Health and other key companies, straight to your email.

About Selectis Health

Selectis Health (OTCMKTS:GBCS) Corporation (OTCMKTS: GBCS) is a U.S.-based specialty healthcare company focused on the research, development and commercialization of proprietary medical technologies and consumer health products. The company develops and markets advanced wound care dressings, orthopedic regenerative implants and novel nutraceutical formulations. Selectis Health’s product portfolio includes scaffold-based healing matrices, bioactive joint support supplements and a range of topical and oral therapeutic agents designed to support tissue regeneration and overall wellness.

Founded in 2012 and headquartered in Miami, Florida, Selectis Health has expanded its operations to serve key markets across North America, Europe and Asia. The company’s manufacturing facilities adhere to current Good Manufacturing Practice (cGMP) standards, and it leverages strategic partnerships to enhance its supply chain, distribution network and regulatory compliance. Over the years, Selectis Health has secured several patents and trademarks for its proprietary biomaterials and delivery systems.

In addition to its core product lines, Selectis Health operates a research and development center focused on emerging regenerative medicine applications, including cellular therapies and 3D-bioprinting technologies. The company’s R&D pipeline encompasses next-generation wound closure devices, orthopedic cartilage scaffolds and synergies with digital health platforms for remote patient monitoring. Selectis Health also offers contract manufacturing services for select partners seeking cGMP-certified production of medical-grade products.

Selectis Health is led by a management team with deep industry experience. John P. Richards serves as President and Chief Executive Officer, bringing over 25 years of leadership in medical device commercialization. Chief Scientific Officer Dr. Maria L. Ortega oversees the company’s R&D efforts, while Chief Financial Officer Peter Zhao manages financial planning and investor relations. The board includes a mix of healthcare veterans and life sciences investors, positioning the company for strategic growth as it advances its product pipeline.

View Selectis Health Profile

More Earnings Resources from MarketBeat